The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype
Open accessAbstract
In the present study, we investigated the role of the CD40L-CD40 pathway in a model of progressive atherosclerosis. ApoE−/− mice were treated with an anti-CD40L antibody or a control antibody for 12 wk. Antibody treatment started early (age 5 wk) or was delayed until after the establishment of atherosclerosis (age 17 wk). In both the early and delayed treatment groups, anti-CD40L antibody did not decrease plaque area or inhibit lesion initiation or age-related increase in lesion area. The morphology of initial lesions was not affected, except for a decrease in T-lymphocyte content. Effects of anti-CD40L antibody treatment on the morphology of advanced lesions were pronounced. In both the early and delayed treatment groups, T-lymphocyte content was significantly decreased. Furthermore, a pronounced increase in collagen content, vascular smooth muscle cell/myofibroblast content, and fibrous cap thickness was observed. In the delayed treatment group, a decrease in lipid core and macrophage content occurred. Interestingly, advanced lesions of anti-CD40L antibody-treated mice exhibited an increased transforming growth factor β1 immunoreactivity, especially in macrophages. In conclusion, both early and delayed treatment with an anti-CD40L antibody do not affect atherosclerotic lesion initiation but do result in the development of a lipid-poor collagen-rich stable plaque phenotype. Furthermore, delayed treatment with anti-CD40L antibody can transform the lesion profile from a lipid-rich to a lipid-poor collagen-rich phenotype. Postulated mechanisms of this effect on plaque phenotype are the down-regulation of proinflammatory pathways and up-regulation of collagen-promoting factors like transforming growth factor β.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,533
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., & Kroczek, R. A. (1998) · Nature · doi:10.1038/35393 · Cited by 2,078
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,028
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
Larsen, C. P., Elwood, E. T., Alexander, D. Z., Ritchie, S. C., Hendrix, R., Tucker-Burden, C., Cho, H. R., Aruffo, A., Hollenbaugh, D., Linsley, P. S., et al. (1996) · Nature · doi:10.1038/381434a0 · Cited by 1,455
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.9.1512 · Cited by 965
Reduction of atherosclerosis in mice by inhibition of CD40 signalling
Mach, F., Schönbeck, U., Sukhova, G. K., Atkinson, E., & Libby, P. (1998) · Nature · doi:10.1038/28204 · Cited by 910
Aruffo, A., Farrington, M., Hollenbaugh, D., Li, X., Milatovich, A., Nonoyama, S., Bajorath, J., Grosmaire, L. S., Stenkamp, R., Neubauer, M., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90668-g · Cited by 814
Mach, F., Schönbeck, U., Sukhova, G. K., Bourcier, T., Bonnefoy, J.-Y., Pober, J. S., & Libby, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1931 · Cited by 732
Cited by
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
Luttun, A., Tjwa, M., Moons, L., Wu, Y., Angelillo-Scherrer, A., Liao, F., Nagy, J. A., Hooper, A., Priller, J., De Klerck, B., et al. (2002) · Nature Medicine · doi:10.1038/nm731 · Cited by 1,068
INFLAMMATION AND ATHEROSCLEROSIS
Hansson, G. K., Robertson, A.-K. L., & Söderberg-Nauclér, C. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100100 · Cited by 1,046
Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis
Hansson, G. K., Libby, P., Schönbeck, U., & Yan, Z.-Q. (2002) · Circulation Research · doi:10.1161/01.res.0000029784.15893.10 · Cited by 1,024
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
New Markers of Inflammation and Endothelial Cell Activation: Part I
Szmitko, P. E., Wang, C.-H., Weisel, R. D., de Almeida, J. R., Anderson, T. J., & Verma, S. (2003) · Circulation · doi:10.1161/01.cir.0000089190.95415.9f · Cited by 738
CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism
André, P., Prasad, K. S. S., Denis, C. V., He, M., Papalia, J. M., Hynes, R. O., Phillips, D. R., & Wagner, D. D. (2002) · Nature Medicine · doi:10.1038/nm0302-247 · Cited by 726
Innate and acquired immunity in atherogenesis
Binder, C. J., Chang, M.-K., Shaw, P. X., Miller, Y. I., Hartvigsen, K., Dewan, A., & Witztum, J. L. (2002) · Nature Medicine · doi:10.1038/nm1102-1218 · Cited by 642
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
Inflammatory Mechanisms: The Molecular Basis of Inflammation and Disease
Libby, P. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00352.x · Cited by 596
Nuclear Factor κB Signaling in Atherogenesis
de Winther, M. P. J., Kanters, E., Kraal, G., & Hofker, M. H. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000160340.72641.87 · Cited by 575
CD40 Signaling and Plaque Instability
Schönbeck, U., & Libby, P. (2001) · Circulation Research · doi:10.1161/hh2401.101272 · Cited by 566
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 498
Mallat, Z., Gojova, A., Marchiol-Fournigault, C., Esposito, B., Kamaté, C., Merval, R., Fradelizi, D., & Tedgui, A. (2001) · Circulation Research · doi:10.1161/hh2201.099415 · Cited by 490
Soluble CD40L and Cardiovascular Risk in Women
Schönbeck, U., Varo, N., Libby, P., Buring, J., & Ridker, P. M. (2001) · Circulation · doi:10.1161/hc4401.099447 · Cited by 459
Autoimmune and Inflammatory Mechanisms in Atherosclerosis
Wick, G., Knoflach, M., & Xu, Q. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104644 · Cited by 431
Biomarkers of Atherosclerotic Plaque Instability and Rupture
Koenig, W., & Khuseyinova, N. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000251503.35795.4f · Cited by 418
Vascular biology of atherosclerosis: overview and state of the art
Libby, P. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03143-0 · Cited by 361
Pinderski, L. J., Fischbein, M. P., Subbanagounder, G., Fishbein, M. C., Kubo, N., Cheroutre, H., Curtiss, L. K., Berliner, J. A., & Boisvert, W. A. (2002) · Circulation Research · doi:10.1161/01.res.0000018941.10726.fa · Cited by 356
Lutgens, E., Gijbels, M., Smook, M., Heeringa, P., Gotwals, P., Koteliansky, V. E., & Daemen, M. J. A. P. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000019729.39500.2f · Cited by 313
Self-citationPlatelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis
Lievens, D., Zernecke, A., Seijkens, T., Soehnlein, O., Beckers, L., Munnix, I. C. A., Wijnands, E., Goossens, P., van Kruchten, R., Thevissen, L., et al. (2010) · Blood · doi:10.1182/blood-2010-01-261206 · Cited by 301
Self-citationAdaptive immunity and atherosclerosis
Andersson, J., Libby, P., & Hansson, G. K. (2010) · Clinical Immunology · doi:10.1016/j.clim.2009.07.002 · Cited by 293
Inflammation and immune system interactions in atherosclerosis
Legein, B., Temmerman, L., Biessen, E. A. L., & Lutgens, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1289-1 · Cited by 292
Self-citationImpact of Interleukin-6 on Plaque Development and Morphology in Experimental Atherosclerosis
Schieffer, B., Selle, T., Hilfiker, A., Hilfiker-Kleiner, D., Grote, K., Tietge, U. J. F., Trautwein, C., Luchtefeld, M., Schmittkamp, C., Heeneman, S., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148135.08582.97 · Cited by 288
Self-citationRay, K. K., & Cannon, C. P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.086 · Cited by 275
Adaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 270
Inoue, S., Egashira, K., Ni, W., Kitamoto, S., Usui, M., Otani, K., Ishibashi, M., Hiasa, K.-I., Nishida, K.-I., & Takeshita, A. (2002) · Circulation · doi:10.1161/01.cir.0000038140.80105.ad · Cited by 256
Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis
Seijkens, T. T. P., van Tiel, C. M., Kusters, P. J. H., Atzler, D., Soehnlein, O., Zarzycka, B., Aarts, S. A. B. M., Lameijer, M., Gijbels, M. J., Beckers, L., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.055 · Cited by 195
Self-citationImmunotherapy for cardiovascular disease
Lutgens, E., Atzler, D., Döring, Y., Duchene, J., Steffens, S., & Weber, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz283 · Cited by 192
Self-citationLessons learned from anti-CD40L treatment in systemic lupus erythematosus patients
Sidiropoulos, P. I., & Boumpas, D. T. (2004) · Lupus · doi:10.1191/0961203304lu1032oa · Cited by 178
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Li, B., Li, W., Li, X., & Zhou, H. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230142931 · Cited by 130
Xia, M., Ling, W., Zhu, H., Wang, Q., Ma, J., Hou, M., Tang, Z., Li, L., & Ye, Q. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000254672.04573.2d · Cited by 96
Metadata
- Authors
- Lutgens, E., Cleutjens, K. B. J. M., Heeneman, S., Koteliansky, V. E., Burkly, L. C., & Daemen, M. J. A. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-06-20
- Volume
- 97
- Issue
- 13
- Pages
- 7464-7469
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2094026225
- Cited by
- 271
- References
- 36
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.